Brief: Y-mAbs’ Danyelza (naxitamab-gqgk) For Treatment Of High-Risk Neuroblastoma Approved In Brazil
23/05/2023 14:31
May 23 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O :
* Y-MABS’ DANYELZA® (NAXITAMAB-GQGK) FOR THE TREATMENT OF
HIGH-RISK NEUROBLASTOMA APPROVED IN BRAZIL
Source text for Eikon: ID:nGNX4Lb0nn
Further company coverage: YMAB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Y-mAbs Therapeutics
See all newsY-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Y-mAbs Therapeutics' Q2 revenue falls 14%
Brief: Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics
Y-mAbs Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary